SC
PCRX icon

Sawyer & Company’s Pacira BioSciences PCRX Stock Holding History

Sawyer & Company’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$7K – 180
2023
Q4 		$7K Hold
200
– – ﹤0.01% 163
2023
Q3 		$6K Buy
+200
New +$7.21K ﹤0.01% 170

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sawyer & Company's PCRX Position: Q1 2024 in Review

Sawyer & Company sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 200 shares — an estimated $7K sold.

Sawyer & Company first reported a position in PCRX in Q3 2023 and held it in 2 quarters. The position peaked at $7K in Q4 2023. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Sawyer & Company reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Sawyer & Company sold 200 Pacira BioSciences shares in Q1 2024, an estimated $7K.
  • Sawyer & Company first reported a position in Pacira BioSciences in Q3 2023 and held it in 2 quarters.
  • Sawyer & Company's Pacira BioSciences position peaked at $7K in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Sawyer & Company's 13F filing for Q1 2024, filed 16 Apr 2024.